Uncategorized
Allergan divests global generics business to Teva Pharma
Allergan announced that Teva Pharmaceuticals Industries Ltd. will acquire Allergan’s global generic pharmaceutical business for $40.5 billion. Allergan will receive $33.75 billion in cash and $6.75 billion in Teva stock.